Not Signed In - Human Genome Sciences Announces Positive Special Protocol Assessment From FDA For Phase 3 Clinical Trials Of LymphoStat-B(TM)
Fri, 27 Oct 2006 07:00 AM EST
... Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has received a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA), agreeing to the Company's Phase 3 clinical development program for LymphoStat-B(TM) (belimumab) in patients with active systemic lupus erythematosus (SLE). [click link for full article] ...
Related Topics
- Clinical Trials
- Genes and Gene Therapy
- Psychopharmacology
- Security Risk Assessment
- Human Genome Epidemiology Network
- Human Papilloma Virus
- Carcinogens
- Growth Hormones
- Growth Hormone
- Pharmacology
- Human Papillomavirus
- Biosafety
- Infectious Diseases
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Clinical Growth Charts
- Tb
- Hormones
- Anatomy
- Tacrolimus ointment
email this page
print this page
bookmark this page
feedback on this page
